Detalles de la búsqueda
1.
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
BMC Cancer
; 23(1): 1000, 2023 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37853341
2.
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
BMC Med
; 19(1): 206, 2021 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34511132
3.
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Future Oncol
; 17(14): 1709-1719, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569983
4.
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Oncologist
; 25(1): e39-e47, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31604903
5.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31669155
6.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413378
7.
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Br J Cancer
; 118(1): 38-42, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29149104
8.
Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
Oncologist
; 23(7): 776-781, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29540602
9.
Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.
Oncologist
; 22(2): 152-157, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28193735
10.
Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Oncologist
; 22(3): 255-263, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28209747
11.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol
; 17(2): 234-242, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26708155
12.
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Oncologist
; 21(6): 762-70, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27245569
13.
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
Adv Exp Med Biol
; 893: 179-187, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26667344
14.
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Oncologist
; 20(3): 307-15, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25657199
15.
Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
Oncologist
; 20(10): 1175-81, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26330460
16.
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Oncologist
; 20(5): 499-507, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25882375
17.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153538
18.
Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Postgrad Med J
; 90(1062): 228-35, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24643262
19.
MARIPOSA-2: Is the treatment worse than the disease?
Med
; 5(2): 115-117, 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340706
20.
Overcoming Central ß-Sheet #6 (Cß6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
Lung Cancer (Auckl)
; 15: 19-27, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38433979